Skip to main content
. 2021 Apr 5;10(7):1509. doi: 10.3390/jcm10071509

Figure 3.

Figure 3

Progression-free survival (PFS) estimation by Kaplan–Meier analysis: (a) PFS analysis in the overall eligible population; (b) PFS analysis in subpopulations of patients initiated on POM/LoDex in the third versus a later line setting; (c) PFS analysis in subpopulations of patients receiving POM/LoDex only versus those receiving additional antimyeloma agents.